Skoltech is an international graduate research-focused university that was founded by the group of world-renowned scientists in 2011. Skoltech's curriculum focuses on technology and innovation, offering Master's programs in 11 technological disciplines. Students receive rigorous theoretical and practical training, design their own research projects, participate in internships and gain entrepreneurial skills in English. The faculty is comprised of current researchers with international accreditation and achievements.

Seminar: “Autonomic Neurology, Rare Diseases, and Biotechnology – from Bedside to the Bench and Back”

We are glad to invite you to a seminar by Prof. Max J Hilz, titled “Autonomic Neurology, Rare Diseases, and Biotechnology – from Bedside to the Bench and Back”

Seminar abstract:

The lecture will address general and sophisticated methods to assess early stages of diseases afflicting the autonomic nervous system, which would compromise quality of life and life expectancy. It will also demonstrate the benefits of advanced autonomic nervous system testing for the identification of incipient but life threatening cardiovascular dysfunction in patients with orphan diseases such as Fabry disease. Examples of specific studies will show how the early diagnosis and subsequent treatment with biotechno-logically engineered therapies can reverse the pathology.

The presentation will show that the close clinical interaction with biotechnology will help refine diagnosis and staging of diseases. Finally, the presentation will address biotechnological treatment perspectives and the value of an early-on interaction between basic scientists and clinical researchers to bring clinically needed basic developments back to the patient.

Speaker introduction:   


Prof. Hilz is the Chair in Autonomic Neurology and Director of the Clinical Department of Autonomic Neurology at the University College London, Institute of Neurology, Queen Square, London, UK. He is also Adjunct Professor of Neurology at Icahn School of Medicine at Mount Sinai, New York, NY, USA, and Professor of Neurology at the University of Erlangen-Nuremberg, Germany. From 1992 until 2013, he held appointments at New York University, New York, NY, as Professor of Neurology, Medicine and Psychiatry.

After initial training in Anesthesia, Intensive Care Medicine and Ear-Nose-and–Throat diseases, he acquired German board certificates in Neurology, Psychiatry, Psychotherapy and in Neurological Intensive Care Medicine and Clinical Neurophysiology. He took the American Boards of Electrodiagnostic Medicine.

His special expertise is the Autonomic Nervous System (ANS). He contributed to the US American ANS specialty examination and was President of several international ANS societies. Currently, he co-chairs the ANS Subspecialty Panel of the European Academy of Neurology.

He focused on central ANS dysfunction and extensively studied rare hereditary diseases, such as Familial Dysautonomia and Fabry disease.

Prof. Hilz is a member of 17 scientific societies, reviewer for 27 scientific journals, editorial board member of Clinical Autonomic Research, Associate Clinical Editor of Autonomic Neuroscience: Basic and Clinical.

He co-authored several guidelines for German, European and US American societies. He published more than 300 scientific articles in peer-reviewed journals and textbooks and gave hundreds of scientific lectures at leading universities and organizations including the United Nations. He mentored more than 50 doctoral theses most of which were evaluated as “magna cum laude”. Several of his co-workers reached leading national and international positions.

Prof. Hilz served as advisor to the European Medicines Agency, EMA, and to leading pharmaceutical companies. Currently, he chairs the global safety committee for an FDA approved phase II trial assessing novel treatment of a neurodegenerative disease.

He is particularly interested in the interaction between basic and clinical science to the benefit of advanced medical care.


If you like to participate and for further information or questions, please Liliya Abaimova.

Share on VK